Apellis Pharmaceuticals, Inc. (APLS): Price-to-Sales Ratio

Corporate company logo of Apellis Pharmaceuticals, Inc. (APLS)

The price-to-sales ratio on the GURU.Markets chart illustrates the valuation trend, where the parameter value equals 4.80 for Apellis Pharmaceuticals (APLS). The development of various therapeutic platforms reduces reliance on a single market. However, geopolitical fragmentation hinders biotechnology exports and international research. Meanwhile, business stability relies on sales of the macular degeneration drug amid moderate revenue growth.

APLS apellis.com Price-to-Revenue Ratio (07/04/2022 - 05/30/2026)

Analytical breakdowns for Apellis Pharmaceuticals Inc (APLS)

- stock value and consensus price forecast:
Stock Price apellis.com|APLS - Price Target Chart
- stock exchange capitalization data:
Market Valuation Apellis Pharmaceuticals Inc|APLS - Enterprise Value
- balance sheet net asset value indicators:
Net Asset Value per Share Apellis Pharmaceuticals|APLS - Company Book Value|Market Value to Book Value Ratio apellis.com|APLS - Aggregate Company Assets
- debt obligations and liquidity statistics:
Debt to Equity Apellis Pharmaceuticals|APLS - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient Apellis Corp|APLS - Company Debts|Debts to Net Assets Apellis Pharmaceuticals Inc|APLS - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Apellis Pharmaceuticals|Critical Liquidity Ratio apellis.com
- earnings and multiples data:
APLS - Net Profit|Expected Net Income Apellis Pharmaceuticals|APLS - P/E Multiple|Forward P/E Multiple Apellis Pharmaceuticals, Inc.|APLS - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Apellis Pharmaceuticals Inc|APLS - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Apellis Pharmaceuticals|APLS - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth apellis.com|APLS - Earnings growth in current year|Expected earnings per share growth for next year Apellis Pharmaceuticals
- total revenue and sales volume data:
APLS - Revenue and Sales Volume|Company Expected Sales Volume apellis.com|APLS - Market Cap to Revenue|Forward P/S Multiple Apellis Pharmaceuticals Inc
Fundamental company analysis:APLS, apellis.com
Product sample of Apellis Pharmaceuticals

For Apellis Pharmaceuticals (APLS), which is rebuilding physician trust following safety crises, market valuation often outpaces the actual commercial success of its drugs. The current price-to-sales ratio measures the premium investors are willing to pay for every dollar of sales; sharp deviations on the chart signal speculative overheating of the asset relative to its actual cash inflows, creating a risk of capital correction.

Who Apellis Pharmaceuticals competes with

P/S Multiple alcon.com (ALC)|Price-to-Revenue Ratio Bausch + Lomb BLCO|GKOS (Glaukos Corp) - Price-to-Sales Ratio|Belite Bio Pharma - P/S Multiple|Price to Sales Ocular Pharma|Harrow, Inc. (HROW) - Price-to-Revenue Ratio|VRDN (viridiantherapeutics.com) - Price-to-Revenue Ratio|Price-to-Revenue Ratio LENZ Therapeutics|Price-to-Revenue Ratio OCS|P/S Multiple EYPT|Price-to-Revenue Coefficient Kodiak Corp|Price-to-Revenue Ratio Aldeyra Therapeutics, Inc. ALDX|Price-to-Revenue Coefficient KALA BIO Inc. (KALA)|IRD: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio OKYO (OKYO Pharma Limited)|adverum.com (ADVM) - Price-to-Revenue Ratio|Price-to-Sales Ratio OTLK (Outlook Therapeutics Corp)|CLSD (Clearside Biomedical) - P/S Multiple|NBY: Market Capitalization-to-Revenue Ratio|P/S Multiple KPRX|P/S Multiple alimerasciences.com (ALIM)|Price-to-Revenue Ratio Eyenovia EYEN|Market Capitalization-to-Revenue Ratio GHSI|OCUP - Price-to-Revenue Ratio|opthea.com (OPT) - Market Cap to Revenue